ProCE Banner Activity

Leukemias: Key Trials From ASH 2019

Conference Coverage
Clinical Thought
Get expert perspective on the key studies in AML and ALL from ASH 2019 that may impact your practice and help you to improve patient outcomes.

Released: February 03, 2020

Expiration: February 01, 2021

No longer available for credit.

Share

Faculty

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, Pfizer, and Stemline and fees for non-CME/CE services from Pfizer and Stemline.